Pharmaceutical

Novo Nordisk strikes $1bn deal for Lexicon’s oral obesity drug

Novo Nordisk has signed a deal worth up to $1bn with Lexicon Pharmaceuticals for the exclusive global rights to oral therapy LX9851.

Mar 29, 2025 - 06:00
Novo Nordisk strikes $1bn deal for Lexicon’s oral obesity drug
Novo Nordisk has signed a deal worth up to $1bn with Lexicon Pharmaceuticals for the exclusive global rights to oral therapy LX9851.
Read the original article

Tags:

Previous Article

Novel Biomarkers May Enhance Early Detection and Monitoring of Kidney Injury

Next Article

Macau approves IASO Bio’s multiple myeloma therapy

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Annexon’s trial of an eye disease drug missed by a mile. The company saw a bull’s eye

STAT+: Annexon’s trial of an eye disease drug missed by...

May 25, 2023

Skyline wins orphan drug designation for retinitis pigmentosa gene therapy

Skyline wins orphan drug designation for retinitis pigm...

Sep 4, 2024

STAT+: Congress’ negotiations over doc pay, health centers fell apart ahead of spending extension

STAT+: Congress’ negotiations over doc pay, health cent...

Jan 18, 2024